Weiyu Chen1,2,3, Miao Li2,4, Muhsin H Younis2, Todd E Barnhart2, Dawei Jiang2, Tuanwei Sun2, Joshua M Lang5,6, Jonathan W Engle2, Min Zhou7,8, Weibo Cai9,10. 1. The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, Zhejiang, China. 2. Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53792, USA. 3. International Institutes of Medicine, the Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, China. 4. Department of Cancer Precision Medicine, Med-X Institute, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China. 5. University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA. 6. Department of Medicine, University of Wisconsin-Madison, Madison, WI, 53705, USA. 7. The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, Zhejiang, China. zhoum@zju.edu.cn. 8. Institute of Translational Medicine, Zhejiang University, Hangzhou, 310009, China. zhoum@zju.edu.cn. 9. Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI, 53792, USA. wcai@uwhealth.org. 10. University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA. wcai@uwhealth.org.
Abstract
PURPOSE: Without a standard test for pancreatic carcinomas, this highly lethal disease is normally diagnosed at its advanced stage, leading to a low survival rate of patients. Trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein, is associated with cell proliferation and highly expressed in most of solid epithelial tumors, including pancreatic cancer. A non-invasive method of imaging Trop-2 would greatly benefit clinical diagnosis and monitoring of pancreatic cancer. In the current study, 89Zr-labeled anti-Trop-2 antibody (AF650) was recruited for the systemic evaluation of Trop-2 as an immunoPET target for pancreatic cancer imaging. METHODS: AF650 was conjugated with desferrioxamine (DFO) and then radiolabeled with 89Zr. Trop-2 expression levels were determined in three pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, and AsPC-1) via western blot, flow cytometry, saturation binding assay, and immunofluorescence staining. The targeting capacity of 89Zr-DFO-AF650 was evaluated in mouse models with subcutaneous xenograft of pancreatic cancers via PET imaging and bio-distribution studies. In addition, a Trop-2-positive orthotopic cancer model was recruited for further validating the targeting specificity of 89Zr-DFO-AF650. RESULTS: BxPC-3 cells expressed high levels of Trop-2, while AsPC-1 and MIA PaCa-2 cells expressed low levels of Trop-2. Additionally, 89Zr-DFO-AF650 exhibited high specificity to Trop-2 in BxPC-3 cells (Kd = 22.34 ± 2.509 nM). In subcutaneous xenograft models, about 28.8 ± 7.63%ID/g tracer accumulated in the BxPC-3 tumors at 120 h post injection, which was much higher than those reaching MIA PaCa-2 (6.76 ± 2.08%ID/g) and AsPC-1 (3.51 ± 0.69%ID/g) tumors (n = 4). More importantly, 89Zr-DFO-AF650 could efficiently distinguish primary tumors in the orthotopic BxPC-3 cancer model, showing high correlation between PET imaging and bio-distribution and sensitivity. CONCLUSIONS: 89Zr-DFO-AF650 can be effectively used to detect pancreatic cancer via Trop-2-mediated immunoPET in vivo, clearly revealing the great potential of Trop-2-based non-invasive imaging in pancreatic cancer detection and treatment monitoring.
PURPOSE: Without a standard test for pancreatic carcinomas, this highly lethal disease is normally diagnosed at its advanced stage, leading to a low survival rate of patients. Trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein, is associated with cell proliferation and highly expressed in most of solid epithelial tumors, including pancreatic cancer. A non-invasive method of imaging Trop-2 would greatly benefit clinical diagnosis and monitoring of pancreatic cancer. In the current study, 89Zr-labeled anti-Trop-2 antibody (AF650) was recruited for the systemic evaluation of Trop-2 as an immunoPET target for pancreatic cancer imaging. METHODS: AF650 was conjugated with desferrioxamine (DFO) and then radiolabeled with 89Zr. Trop-2 expression levels were determined in three pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, and AsPC-1) via western blot, flow cytometry, saturation binding assay, and immunofluorescence staining. The targeting capacity of 89Zr-DFO-AF650 was evaluated in mouse models with subcutaneous xenograft of pancreatic cancers via PET imaging and bio-distribution studies. In addition, a Trop-2-positive orthotopic cancer model was recruited for further validating the targeting specificity of 89Zr-DFO-AF650. RESULTS: BxPC-3 cells expressed high levels of Trop-2, while AsPC-1 and MIA PaCa-2 cells expressed low levels of Trop-2. Additionally, 89Zr-DFO-AF650 exhibited high specificity to Trop-2 in BxPC-3 cells (Kd = 22.34 ± 2.509 nM). In subcutaneous xenograft models, about 28.8 ± 7.63%ID/g tracer accumulated in the BxPC-3 tumors at 120 h post injection, which was much higher than those reaching MIA PaCa-2 (6.76 ± 2.08%ID/g) and AsPC-1 (3.51 ± 0.69%ID/g) tumors (n = 4). More importantly, 89Zr-DFO-AF650 could efficiently distinguish primary tumors in the orthotopic BxPC-3 cancer model, showing high correlation between PET imaging and bio-distribution and sensitivity. CONCLUSIONS: 89Zr-DFO-AF650 can be effectively used to detect pancreatic cancer via Trop-2-mediated immunoPET in vivo, clearly revealing the great potential of Trop-2-based non-invasive imaging in pancreatic cancer detection and treatment monitoring.
Authors: Doru M Paul; Cristina M Ghiuzeli; Josephine Rini; Christopher J Palestro; Edward K Fung; Maged Ghali; Eran Ben-Levi; Andrew Prideaux; Shankar Vallabhajosula; Elizabeta C Popa Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15
Authors: Miao Li; Dawei Jiang; Todd E Barnhart; Tianye Cao; Jonathan W Engle; Weiyu Chen; Weibo Cai Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: Fatemeh Kaghazchi; Austin J Borja; Emily C Hancin; Abhijit Bhattaru; Donald K E Detchou; Siavash Mehdizadeh Seraj; Chaitanya Rojulpote; Soren Hess; Lorenzo Nardo; Peter E Gabriel; Scott M Damrauer; Thomas J Werner; Abass Alavi; Mona-Elisabeth Revheim Journal: Am J Nucl Med Mol Imaging Date: 2021-04-15
Authors: Xihua Lian; Amy Scott-Thomas; John G Lewis; Madhav Bhatia; Sean A MacPherson; Yiming Zeng; Stephen T Chambers Journal: Int J Mol Sci Date: 2022-05-16 Impact factor: 6.208